Public Relations (PR)

Experts: Sprout needs to show Addyi is not Viagra for women

Experts: Sprout needs to show Addyi is not Viagra for women

Contrary to popular belief, Addyi is not the female Viagra. That's the message drug-maker Sprout must get across to doctors and patients in the coming weeks.

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.

Healthcare reimagined: Fortner finesses McKesson's bold vision

Healthcare reimagined: Fortner finesses McKesson's bold vision

From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.

Novartis exec: Pharma culture can be stumbling block to creativity

Novartis exec: Pharma culture can be stumbling block to creativity

By

It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.

Smirnoff switches over to Weber's health practice

Smirnoff switches over to Weber's health practice

By

Weber Shandwick hired Susan Smirnoff away from the healthcare practice of Ruder Finn, where she had spent more than three decades.

Astellas serves up dose of "reality" in DTC effort

Astellas serves up dose of "reality" in DTC effort

By

The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.

Novo, Deen agree to suspend their relationship

Novo, Deen agree to suspend their relationship

By

Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.

Novo Nordisk in Paula Deen holding pattern

Novo Nordisk in Paula Deen holding pattern

By

The drug maker says it has spoken to Deen about her racist comments, but an opaque company statement indicates the Danish firm has not cut ties with the now-former Food Network star.

It's Consumer's Choices as Guidelines Change

It's Consumer's Choices as Guidelines Change

Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.

Business briefs: GlaxoSmithKline, Burson-Marsteller

GSK says 2013 will be a springboard for future growth, Burson-Marsteller hands out two new executive titles.

Home HIV test maker preps TV ad fusillade, lures Pfizer marketer

By

OraSure, the maker of the recently-approved home HIV test, has hired an experienced consumer marketer from Pfizer to head up the launch as it readies a TV ad campaign.

Company news: Edelman, CMS, McKesson

Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.

With untitled letter, FDA signals press materials aren't exempt

By

The FDA has issued a rare untitled letter concerning a pitch letter - a reminder that the agency does not consider press materials to be exempted from its oversight.

JAMA shows a knack for multi-channel outreach

By

The fan base of the AMA's publishing arm grew 115% in the second quarter.

Komen announces executive shakeup

Komen announces executive shakeup

By

The non-profit announced Thursday that it is on the hunt for a new president and two new board members, and that its beleaguered CEO will step down.

Company news: Roche, Porter Novelli

Roche shutters its Nutley, NJ, R&D site, and Porter Novelli names a new CEO.

Did FDA's Vytorin warning negatively impact health outcomes?

By

An analysis of the FDA's handling of the Vytorin debacle points to a need for better public-health warnings about medications, researchers say.

Consumers to disease: You're not the boss of me

By

A global study of consumer attitudes towards health found evidence for the "empowered consumer" hypothesis, with respondents expressing a greater sense of control over and responsibility for their health.

Shake-up at top for J&J, as Weldon exits CEO post

By

The most recent Johnson & Johnson recall may officially be CEO William Weldon's last. Alex Gorsky will become CEO as of April 26, the company said, and Weldon will stay on as chairman of the board of directors.

Poll shows J&J rep is dented, not destroyed

By

Despite recalls, a settlement over allegations of Medicare Fraud and illicit marketing of off-label drug use, a poll by research group Harris Interactive indicates that Johnson & Johnson's corporate reputation is dented, but intact.

Komen, caught up in the culture wars, nurses damaged brand

Komen, caught up in the culture wars, nurses damaged brand

By

Cowed by a fierce and lighting-quick backlash fueled by angry Tweets and Facebook posts, The Susan G. Komen for the Cure Foundation is backpedaling, but is it too late to reverse the reputation damage?

J&J names new PR chief as consumer pharma head retires

By

Johnson & Johnson is promoting the head of its global vision care business to serve as its marketing and PR chief, replacing global OTC chairman Brian Perkins, who is retiring, in that role.

Advil Congestion effort ties traffic gridlock to cold and flu misery

Advil Congestion effort ties traffic gridlock to cold and flu misery

By

Don't tell the New York Post, but Pfizer is boosting bike lanes as part of an Advil promotion.

Boehringer's Pharma-ville could salve industry's bad reputation

Boehringer's Pharma-ville could salve industry's bad reputation

By

Boehringer Ingelheim is hoping to create a new Facebook phenomenon with the development of a pharma civilization game that could give industry reputation a shot in the arm.

Piercing the veil, but missing the value of medicine's industry ties

By

ProPublica's Dollars for Docs database has grown richer in pharma company payments but falls short in putting context around those expenditures, say industry-side critics.

Did a PR firm's lapse give hackers keys to Pfizer Facebook page?

By

Contrary to reports, hackers' brief takeover of the Pfizer Facebook page was probably not due to a security lapse by the social networking giant, security experts say.

Bayer beefs up Ob/Gyn sales calls

Bayer beefs up Ob/Gyn sales calls

By

Pfizer has usurped Merck as the most admired drug company among obstetricians and gynecologists, according to SDI's Pharmaceutical Company Image 2011 study, while Bayer increased its sales presence in that specialty significantly.

UK PR pitch could portend US acquisitions for AstraZeneca

By

AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.

People news: Porter Novelli and Impax Labs

Porter Novelli named Susan Hayes global director of health, effective immediately.

J&J cleaves McNeil from consumer in move to restore OTC brands

By

Johnson & Johnson is reorganizing its troubled McNeil Consumer Healthcare unit in the US and installing new leadership.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.